BENEFIT
Tenshi Kaizen’s InstaPillTM – is a new paradigm in pharmaceutical technology solutions. It is a differentiated technology platform that is well-positioned to deliver compelling solutions for dosage convenience on-the-go with its orally disintegrating tablets (ODTs). ODTs from InstaPillTM have a one-of-a-kind dosage format which can be consumed without water and disperses in the mouth in less than 10 seconds. This fast dissolving tablet format helps to address common issues such as difficulty in swallowing, mainly by pediatric and geriatric patients, dosage convenience over traditional solid oral dosage forms, lending itself to extending the product offerings by keeping the consumer’s needs in mind.
Why partner with InstaPillTM?
We are a partner of choice for contract ODT formulation and manufacture, to facilitate Brand Life cycle management solutions. With InstaPillTM proprietary solutions, our platform can be easily extended to a wide range of pharmaceutical products across multiple therapeutic classes and dosage strengths. In addition to InstaPillTM infusing new life to a brand and its positioning, it also offers solutions to develop a product enhanced market claims, novel delivery format, superior caregiver and patient experience and potential exclusivities in the market through regulatory strategies including 505(b)(2).
- Innovative format with strong consumer preference
- Taste masked & flavor-enhanced
- Novel format with Multiple packaging formats
- Differentiated brand claims
The InstaPillTM Platform Advantage
Formulation Approach
- Innovative and collaborative approach to formulation development with partner
- Gelatin free formulations
- Flexibility to cater to specific pack counts per customer and indication requirements
Technical Capabilities
- Introduction of detailed process controlled strategies
- High assurance of content uniformity
- Accelerated product development capabilities
- Design and conduct pilot and pivotal clinical programs supervised by in-house experts
- Packaging lines conform to serialization requirements of all leading health authorities
Manufacturing Facilities
- State of the art manufacturing facilities in India and in the USA
- Fully Integrated operations
- Extensive automation to provide high cGMP compliance
- Well established process control strategy
- Capacity with space allocated for expansion to produce 200 million RDTs annually
- Layout facilities scalability and capacity enhancement
Partnership Opportunities
- Brand and molecule life cycle management activities for existing products
- Several products under development and under filing available for licensing combined with supply arrangements
- Customised solutions for potential market exclusivity
- Potential opportunity for combination drug products
